|
|
|
|
| LEADER |
03618nmm a2200301 u 4500 |
| 001 |
EB000709237 |
| 003 |
EBX01000000000000000562319 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
140122 ||| eng |
| 020 |
|
|
|a 9783709189030
|
| 100 |
1 |
|
|a Guggenbichler, J.-P.
|e [editor]
|
| 245 |
0 |
0 |
|a New Aspects for Treatment with Fosfomycin
|h Elektronische Ressource
|c edited by J.-P. Guggenbichler
|
| 250 |
|
|
|a 1st ed. 1987
|
| 260 |
|
|
|a Vienna
|b Springer Vienna
|c 1987, 1987
|
| 300 |
|
|
|a VIII, 144 p. 24 illus
|b online resource
|
| 505 |
0 |
|
|a Summary—Zusammenfassung -- Activity of Fosfomycin Against Grampositive Bacteria -- Influence of Intracellularly Active Antibiotics (Fosfomycin, Rifampin, Sulfamethoxazole, Trimethoprim) on Normal Neutrophil Function in vitro -- Investigation of Fosfomycin Concentrations in the Cerebrospinal Fluid (CSF) and Its Clinical Significance in Neurosurgical Patients -- Antimicrobial Therapy of Bacterial Meningitis in Premature- and Newborn Infants and Shunt Infections -- Fosfomycin in Cerebral and Spinal Abscesses -- Fosfomycin in the Treatment of Chronic Osteitis -- Resistance of Intracellular Killing of Staphylococci by Macrophages as New Pathophysiologic Concept of Acute Hematogenous Osteomyelitis in Children and Therapeutic Consequences -- Fosfomycin in the Treatment of Severe Urinary Tract Infections -- Penetration of Fosfomycin into Heart Valves, Subcutaneous and Muscle Tissue of Patients Undergoing Open Heart Surgery -- Fosfomycin in the Treatment of Pulmonary Infections Combined wi
|
| 653 |
|
|
|a Critical care medicine
|
| 653 |
|
|
|a Internal medicine
|
| 653 |
|
|
|a Intensive / Critical Care Medicine
|
| 653 |
|
|
|a Internal Medicine
|
| 653 |
|
|
|a Pharmacology
|
| 653 |
|
|
|a Pharmacology/Toxicology
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b SBA
|a Springer Book Archives -2004
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-7091-8903-0?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616
|
| 520 |
|
|
|a Fosfomycin is an antimicrobial substance which is available since several years. In earlier clinical studies an oral preparation with poor absorption in a low dosage resulted in inadequate therapeutic results. The presently used parenteral administration in a dosage range of up to 250 mg/kg BW however allowed us to appreciate several unique properties of this drug which make it valuable in the treatment of serious bacterial infections. Due to its small molecular weight and complete lack of protein binding a favorable penetration in tissues and deep compartments (e.g., meninges, bone, heart valves) was observed. In addition fosfomycin shows a remarkably low toxicity and even protects from the nephrotoxigenic effects of aminoglycosides and other drugs. Earlier problems in antimicrobial susceptibility testing have been solved by addition of glucose 6 phosphate into the growth medium. Fosfomycin, the first representative of a completely new class of antibiotics does not show cross-resistance with other antibiotics; therefore pathogens of nosocomial infections, particularly methicillin- und gentamicin-resistant staphylococci are mostly susceptible to this antibiotic. Clinical investigations show a favorable therapeutic outcome in severe nosocomial infections despite of previous therapeutic approaches with various other potent antibiotics. In an international symposium in Mexico City the available clinical experience with this drug was presented and indications for the use of this antibiotic were established. Prof Dr. K. H. Spitzy Contents Summary-Zusammenfassung .........................................................
|